Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa–acne inversa: evidence from the national Italian registry

This is the authors' abstract. We don't add key points for this paper.

Funding sources: none. Conflicts of interest: L.N. has worked on the advisory boards of Novartis, Amgen, Janssen‐Cilag and Pfizer and served as a consultant to Lilly. Dear Editor, Hidradenitis suppurativa–acne inversa (HS‐AI) is a chronic inflammatory skin condition that involves the folliculopilosebaceous units. Histopathological studies have suggested that the occlusion of the follicular infundibulum and both innate and adaptive immunity play central roles.1 2 Limited data regarding the clinical aspects and prognosis of HS‐AI are available.3 This paper presents data collected within the newly implemented Italian registry of patients with HS‐AI. This was a cross‐sectional study on baseline data of a cohort of consecutive patients with a new diagnosis of HS‐AI, prospectively observed within a network of Italian dermatology departments. Presence and recurrence, for at least 6 months, of nodules, abscesses, draining sinuses and secondary retracting scars localized on the axillae, sub‐ and intermammary areas, inguinal folds, buttocks and perianal areas were considered as inclusion criteria.4